Somaxon CEO resigns

Somaxon CEO Kenneth M. Cohen has announced this resignation, effective December 31, 2007. The company's non-executive board chairman David F. Hale will serve as interim CEO until a permanent replacement for Cohen is hired. Specific reasons for Cohen's resignation were not outlined in the announcement, though the company noted that "management changes are part of a transition plan." Somaxon is based in San Diego, CA and is developing psychiatry and neurology treatments.

- see Somaxon's release

Suggested Articles

After delivering a "positive surprise" in December, Biogen is painting a fuller picture of its lupus drug.

A new CRISPR technique neutralizes SARS-CoV-2 by scrambling the virus' genetic code. It could prove useful for fighting other viruses, like influenza.

The deal, which follows a bidding war with AcelRx, gives Melinta another approved antibiotic and potentially complementary R&D expertise.